



## **Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018**

April 11, 2018

- Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 11, 2018-- [Exelixis, Inc.](http://www.exelixis.com) (NASDAQ: EXEL) announced today that its first quarter 2018 financial results will be released on Wednesday, May 2, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website.

To access the webcast link, log onto [www.exelixis.com](http://www.exelixis.com) and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 7895176 to join by phone.

A telephone replay will be available until 8:30 p.m. EDT on May 4, 2018. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 7895176. A webcast replay will also be archived on [www.exelixis.com](http://www.exelixis.com) for one year.

### **About Exelixis**

Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring these medicines to patients globally. We are steadfast in our commitment to prudently reinvest in our business to maximize the potential of our pipeline. We intend to supplement our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis recently earned a spot on Deloitte's Technology Fast 500 list, a yearly award program honoring the 500 fastest-growing companies over the past four years. For more information about Exelixis, please visit [www.exelixis.com](http://www.exelixis.com), follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

*Exelixis and the Exelixis logo are registered U.S. trademarks.*

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180411006318/en/>

Source: Exelixis, Inc.

*Exelixis, Inc.*

*Susan Hubbard, 650-837-8194*

*Executive Vice President, Public Affairs & Investor Relations*

[shubbard@exelixis.com](mailto:shubbard@exelixis.com)